Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) and Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, dividends and valuation.
Profitability
This table compares Lisata Therapeutics and Zealand Pharma A/S’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lisata Therapeutics | N/A | -154.76% | -120.19% |
| Zealand Pharma A/S | 67.13% | 19.70% | 18.27% |
Earnings & Valuation
This table compares Lisata Therapeutics and Zealand Pharma A/S”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lisata Therapeutics | $100,000.00 | 123.17 | -$16.59 million | ($1.88) | -0.61 |
| Zealand Pharma A/S | $1.40 billion | 1.84 | $977.29 million | $6.81 | 5.28 |
Zealand Pharma A/S has higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Lisata Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Zealand Pharma A/S has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Lisata Therapeutics and Zealand Pharma A/S, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lisata Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
| Zealand Pharma A/S | 0 | 9 | 1 | 1 | 2.27 |
Institutional & Insider Ownership
8.9% of Lisata Therapeutics shares are held by institutional investors. 8.4% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Zealand Pharma A/S beats Lisata Therapeutics on 10 of the 14 factors compared between the two stocks.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage biopharmaceutical company developing therapies for cancer and other serious diseases. The company’s research focuses on improving the delivery of treatments to solid tumors. Its lead investigational product, certepetide (also known as LSTA1 or CEND-1), is a peptide being studied in combination with existing cancer therapies. Clinical development has included pancreatic cancer and other solid tumors; certepetide is not an approved commercial treatment. Lisata adopted its current name in 2022 following a merger involving Cend Therapeutics and the former Caladrius Biosciences.
About Zealand Pharma A/S
Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions. The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
